CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
IDN-6556drug
Likely dose
IDN-6556 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02230683
NCT02230683Phase 2Completed
CompareCT.gov

An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Conatus Pharmaceuticals Inc.·interventional·Posted Sep 3, 2014·Updated Dec 21, 2016

In Brief

A Phase 2 clinical trial evaluating IDN-6556 for Liver Cirrhosis and 2 related conditions. Completed, enrolled 23 participants across 16 sites.

Detailed Summary

This is an open-label pilot study to evaluate the safety, tolerability, and efficacy of IDN-6556 in treating portal hypertension in subjects with liver cirrhosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis, Hepatic Cirrhosis, Portal Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 3, 2014
Enrollment StartAug 1, 2014
Primary CompletionMay 1, 2015
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.8 years ago

Interventions

IDN-6556drug

25 mg BID